Skip to Content

Join the 'Xultophy 100 / 3.6' group to help and get support from people like you.

Xultophy 100 / 3.6 News

Related terms: xultophy

Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection)

Posted 13 days ago by Drugs.com

PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection). Xultophy 100/3.6 is a once-daily, combination of Tresiba (insulin degludec injection) and Victoza (liraglutide) injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily.1 Xultophy 100/3.6 enters into a new class of diabetes treatments that combine a basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single, once-daily injection. "Novo Nordisk is committed to discovering and developing new medicines, like ... Read more

Related support groups: Diabetes, Type 2, Victoza, Liraglutide, Tresiba, Insulin Degludec, Xultophy 100/3.6, Insulin Degludec/liraglutide

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2